Spots Global Cancer Trial Database for Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Official Title: Clinical Study of Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of Extensive Stage Small Cell Lung Cancer
Study ID: NCT05001412
Conditions
Interventions
Study Description
Brief Summary: The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.
Detailed Description: Camrelizumab is a humanized PD-1 monoclonal antibody. Camrelizumab combined with the antiangiogenic drug apatinib has achieved good efficacy in extensive small-cell lung cancer. Median OS is 8.4 months. In our study, subjects with extensive stage small cell lung cancers receive 2 cycles of chemotherapy followed by carrizumab combined with apatinib and chemotherapy. we hope to achieve a better outcome.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Contact Details
Name: Chengzhi Zhou, MD
Affiliation: The First Affiliated Hospital of Guangzhou Medical University
Role: STUDY_DIRECTOR
Name: Xin Chen, MD
Affiliation: Zhujiang Hospital affiliated to Southern Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
